Logo image of SMMT

SUMMIT THERAPEUTICS INC (SMMT) Stock Fundamental Analysis

NASDAQ:SMMT - Nasdaq - US86627T1088 - Common Stock - Currency: USD

22.12  -0.94 (-4.08%)

After market: 22.2001 +0.08 (+0.36%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to SMMT. SMMT was compared to 571 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for SMMT as it has an excellent financial health rating, but there are worries on the profitability. SMMT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SMMT has reported negative net income.
In the past year SMMT has reported a negative cash flow from operations.
SMMT had negative earnings in 4 of the past 5 years.
In the past 5 years SMMT always reported negative operating cash flow.
SMMT Yearly Net Income VS EBIT VS OCF VS FCFSMMT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200M -400M -600M

1.2 Ratios

SMMT's Return On Assets of -122.29% is on the low side compared to the rest of the industry. SMMT is outperformed by 80.28% of its industry peers.
Looking at the Return On Equity, with a value of -140.42%, SMMT is doing worse than 63.59% of the companies in the same industry.
Industry RankSector Rank
ROA -122.29%
ROE -140.42%
ROIC N/A
ROA(3y)-131%
ROA(5y)-86.39%
ROE(3y)-320.01%
ROE(5y)-201.72%
ROIC(3y)N/A
ROIC(5y)N/A
SMMT Yearly ROA, ROE, ROICSMMT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500 -500

1.3 Margins

SMMT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SMMT Yearly Profit, Operating, Gross MarginsSMMT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K -8K -10K

More info and screens

8

2. Health

2.1 Basic Checks

SMMT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SMMT has more shares outstanding
Compared to 5 years ago, SMMT has more shares outstanding
SMMT has a better debt/assets ratio than last year.
SMMT Yearly Shares OutstandingSMMT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M
SMMT Yearly Total Debt VS Total AssetsSMMT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

An Altman-Z score of 154.37 indicates that SMMT is not in any danger for bankruptcy at the moment.
The Altman-Z score of SMMT (154.37) is better than 99.64% of its industry peers.
There is no outstanding debt for SMMT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 154.37
ROIC/WACCN/A
WACC9.44%
SMMT Yearly LT Debt VS Equity VS FCFSMMT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M 200M 300M 400M

2.3 Liquidity

SMMT has a Current Ratio of 8.31. This indicates that SMMT is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of SMMT (8.31) is better than 73.00% of its industry peers.
SMMT has a Quick Ratio of 8.31. This indicates that SMMT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 8.31, SMMT is in the better half of the industry, outperforming 73.18% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.31
Quick Ratio 8.31
SMMT Yearly Current Assets VS Current LiabilitesSMMT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for SMMT have decreased strongly by -50.00% in the last year.
Looking at the last year, SMMT shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)-50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-166.67%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 36.90% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-100.99%
EPS Next 2Y-67.21%
EPS Next 3Y-57.16%
EPS Next 5Y36.9%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SMMT Yearly Revenue VS EstimatesSMMT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2B 4B 6B
SMMT Yearly EPS VS EstimatesSMMT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4 6 8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SMMT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SMMT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SMMT Price Earnings VS Forward Price EarningsSMMT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SMMT Per share dataSMMT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4

4.3 Compensation for Growth

SMMT's earnings are expected to decrease with -57.16% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-67.21%
EPS Next 3Y-57.16%

More info and screens

0

5. Dividend

5.1 Amount

SMMT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SUMMIT THERAPEUTICS INC

NASDAQ:SMMT (2/21/2025, 8:00:02 PM)

After market: 22.2001 +0.08 (+0.36%)

22.12

-0.94 (-4.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-30 2024-10-30/bmo
Earnings (Next)03-13 2025-03-13/bmo
Inst Owners10.1%
Inst Owner Change9.52%
Ins Owners84.57%
Ins Owner Change0.61%
Market Cap16.31B
Analysts83.08
Price Target34.24 (54.79%)
Short Float %18.09%
Short Ratio9.18
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-29.98%
Min EPS beat(2)-42.31%
Max EPS beat(2)-17.64%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.71%
PT rev (3m)-6.75%
EPS NQ rev (1m)-5.23%
EPS NQ rev (3m)-5.23%
EPS NY rev (1m)-1.4%
EPS NY rev (3m)2.21%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 37.25
P/tB 37.42
EV/EBITDA N/A
EPS(TTM)-0.27
EYN/A
EPS(NY)-0.42
Fwd EYN/A
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)-0.15
OCFYN/A
SpS0
BVpS0.59
TBVpS0.59
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -122.29%
ROE -140.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-131%
ROA(5y)-86.39%
ROE(3y)-320.01%
ROE(5y)-201.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 130.93%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.31
Quick Ratio 8.31
Altman-Z 154.37
F-Score6
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)45.61%
Cap/Depr(5y)34.59%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-166.67%
EPS Next Y-100.99%
EPS Next 2Y-67.21%
EPS Next 3Y-57.16%
EPS Next 5Y36.9%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-39.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-152.44%
EBIT Next 3Y-52.07%
EBIT Next 5YN/A
FCF growth 1Y-99.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-101.77%
OCF growth 3YN/A
OCF growth 5YN/A